ArticleScientific reports2025
Bioinformatics analysis identifies BST1 as a potential therapeutic target linked to neutrophil extracellular traps in patients with acute liver failure.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring blood transcriptional signatures for thrombosis diagnosis in critically ill patients with COVID-19.Blood vessels, thrombosis & hemostasis · 2026Article
- Identification of Serum BST1 as a Biomarker to Predict Coronary Artery Lesions in Children with Kawasaki Disease Based on 4D-DIA Quantitative Proteomics.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Acute on chronic liver failure (ACLF) is a critical condition with a high mortality rate; however, the underlying mechanisms driving its progression remain poorly understood. Neutrophil extracellular traps (NETs), a recently discovered mechanism of cell death, may play a significant role in this process. Although NETs has been found in a variety of liver diseases, its specific mechanism in regulating the development of ACLF is not clear. Here, we sought to identify key NETs-related genes associate with ACLF. In this study, gene expression data from 24 whole blood samples, including 7 healthy donors and 17 ACLF patients, were downloaded from the Gene Expression Omnibus database. Various bioinformatics analyses, including Weighted Gene Co-expression Network Analysis (WGCNA) and CIBERSORT, were performed to further analyse and compare the differential genes between patients with acute on chronic liver failure and healthy groups. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed on the differential genes. Differentially expressed genes (DEGs) were analyzed against 69 known NETs-related genes, and a genetic diagnostic model for ACLF patients was established based on the analysis results. In addition, we used an unsupervised clustering method to assess immune infiltration and biological differences based on NETs-related genes. Finally, mice peripheral blood was collected for RT-qPCR verification. A total of 1694 DEGs were identified, and the biological functions and signaling pathways closely related to ACLF were monocyte differentiation and immune-metabolic processes. Twenty-seven expression modules were obtained by WGCNA, among which the ME pink and ME cyan module had the highest correlation with ACLF. The intersection of the results from both analyses with 69 NETs-related genes identified 13 key genes (FCAR, MMP9, ITGAM, DYSF, ALPL, MPO, MGAM, TLR8, BST1, ELANE, TLR4, TLR2, PADI4). Subsequently, CIBERSORT analysis revealed that immune cells, such as M0-type macrophages, activated memory CD4 T cells, and plasma cells, might play an important role in ACLF. Additionally, NETs-related genes were closely associated with immune infiltration. TLR4, BST1, MGAM, DYSF, and ALPL were significantly associated with immune cells. The results of RT-qPCR on mice peripheral blood showed that BST1 expression increased significantly. BST1 may be reliable marker for the diagnosis of ACLF patients, and these results may contribute to a better understanding of the underlying molecular mechanisms of ACLF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.